Deliver Your News to the World

Canon U.S. Life Sciences Presents Information On Genetic Diagnostics And Screening Using Microfluidics Technology At µTAS2006 In Tokyo


Canon U.S.A. R&D Subsidiary Plans to Leverage Caliper Life Sciences’ Technology To Create Future Innovations for Genetic Diagnostics and Screening

LAKE SUCCESS, N.Y., October 31, 2006 – Canon U.S.A., Inc., today announced that Canon U.S. Life Sciences, Inc., is using Caliper Life Sciences’ LabChip microfluidics technology and industry techniques in an effort to help develop future genetic diagnostic and screening solutions. Information will be presented at the 10th International Conference on Miniaturized Systems for Chemistry and Life Sciences (µTAS2006) in Tokyo, November 6th - 9th.

Canon U.S. Life Sciences is seeking to leverage Caliper’s microfluidics technology and industry thermal melting analysis techniques to shorten the processing time, lower the cost of gene diagnosis, and enable rapid review of genes in clinical environments.

In addition, the microfluidics technology is based on the manipulation of nanoliter size volumes of patient samples to amplify genes, and the thermal melting analysis techniques use thermal energy to identify small differences in specific genes. The combination of these technologies is expected to offer the opportunity to create gene diagnosis and screening instruments that are more precise than current methods.

“More efficient and precise genetic screening will be an essential part of the future medical diagnosis market,” said Takayoshi Hanagata, chairman and chief executive officer, Canon U.S. Life Sciences, Inc. “Working with technologies like Caliper’s, Canon is seeking to design and develop quality genetic diagnosis innovations that will help physicians to rapidly diagnose genes to help identify and treat potential genetic disorders or abnormalities.”

In the future, Canon U.S. Life Sciences hopes to be able to utilize Canon’s extensive expertise and experience in optics, sensor technology and precision instrument innovation to produce future products for the life sciences industry.

About Caliper Life Sciences, Inc.
Caliper Life Sciences, Inc. (NASDAQ: CALP) is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. Through the Caliper Driven program, life science and diagnostic companies can access Caliper’s leading microfluidics patent estate and automation technologies to drive innovation and remain competitive in an increasingly complex healthcare industry. Caliper’s products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at

About Canon U.S. Life Sciences, Inc.
Canon U.S. Life Sciences, Inc., is dedicated to exploring potential applications of Canon’s core technologies to the field of life sciences. The company plans to identify and commercially develop life science solutions with potential applications in diagnostics and medical instrumentation. Canon U.S. Life Sciences is a subsidiary of Canon U.S.A., Inc., and is headquartered in Rockville, Maryland.
For more information, visit

About Canon U.S.A., Inc.
Canon U.S.A., Inc. delivers consumer, business-to-business, and industrial imaging solutions. The company is listed as one of Fortune’s Most Admired Companies in America and is rated #35 on the BusinessWeek list of “Top 100 Brands.” Its parent company Canon Inc. (NYSE:CAJ) is a top patent holder of technology, ranking second overall in the U.S. in 2005, with global revenues of $31.8 billion. For more information,

# # #

All referenced product names, and other marks are registered trademarks of their respective owners.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.